Trump’s executive order on drug pricing could be a booster for Indian pharma industry

Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LtGwUZb
via IFTTT